How should Vyvanse (lisdexamfetamine) be initiated, dosed, and monitored in a 12‑year‑old child with ADHD?

Vyvanse for a 12-Year-Old with ADHD

For a 12-year-old with ADHD, start Vyvanse at 30 mg once daily in the morning, titrate weekly by 10-20 mg increments based on response up to a maximum of 70 mg/day, and monitor height, weight, pulse, and blood pressure at each visit. 1

Initiation Strategy

Begin with 30 mg once daily in the morning. 1 The FDA label for Vyvanse specifies this as the starting dose for pediatric patients ages 6-17 years with ADHD. This differs from older amphetamine dosing guidelines that suggested starting at 2.5-5 mg 2, but lisdexamfetamine's prodrug formulation and extended-release profile warrant this higher starting point.

• Administer in the morning after waking
• Can be taken with or without food (food delays peak effect by ~1 hour but doesn't affect overall exposure) 1
• Capsules can be swallowed whole or opened and mixed with water for immediate consumption

Titration Protocol

Increase dose weekly by 10-20 mg increments until optimal response is achieved, up to maximum 70 mg/day. 1

The systematic approach:

• Week 1: 30 mg daily
• Week 2: 40 mg daily (if inadequate response)
• Week 3: 50 mg daily (if inadequate response)
• Week 4: 60 mg daily (if inadequate response)
• Week 5: 70 mg daily (maximum dose if needed)

This contrasts with older methylphenidate titration schedules that used 5-10 mg weekly increases 2, but reflects lisdexamfetamine's unique pharmacokinetics with gradual conversion to active dextroamphetamine 1.

Monitoring Requirements

Baseline Assessment (Before Starting)

• Height and weight (plot on growth charts)
• Blood pressure and pulse
• Cardiac history: specifically ask about syncope, chest pain with exercise, family history of sudden cardiac death, Wolf-Parkinson-White syndrome, hypertrophic cardiomyopathy, long QT syndrome 3, 2
• Psychiatric screening: assess for psychosis, mania, suicidal ideation, substance use 4

Ongoing Monitoring Schedule

During titration (weeks 1-5):

• Weekly contact (phone or visit) to assess response and side effects 2
• Obtain parent AND teacher rating scales (ADHD-RS-IV or similar) 2
• Document specific target symptoms

Maintenance phase (after dose optimization):

• Monthly visits initially until symptoms stabilized 2
• Then quarterly visits minimum
• At each visit measure: 5
  • Height (watch for growth deceleration)
  • Weight (decreased appetite is most common side effect)
  • Pulse (monitor for increases >7 bpm from baseline)
  • Blood pressure (watch for increases ~3-4 mmHg systolic/diastolic)

Parameters Requiring Special Attention

Growth monitoring is critical: Studies show mean decreases of -0.5 kg/m² BMI and shifts to lower growth percentiles over 2 years 6. The MTA study found 1-2 cm height reduction with consistent stimulant use 3.

Cardiovascular thresholds: In long-term studies, 7% of children met potentially clinically important high pulse criteria, 22% of children met high systolic BP criteria, and 39% met high diastolic BP criteria at one or more visits 6. These don't necessarily require discontinuation but warrant closer monitoring.

Expected Response Timeline

Efficacy begins at 1.5 hours post-dose and lasts 13 hours. 7, 8 This is lisdexamfetamine's key advantage—once-daily dosing with all-day coverage including homework time. Peak plasma levels of active dextroamphetamine occur at 3.5 hours 1.

Effect sizes are large:

• SKAMP deportment scale: effect size -1.73 7
• Mean ADHD-RS-IV improvement: -25.8 points from baseline 6
• 77-80% of patients achieve CGI-Improvement scores of "much improved" or "very much improved" 6, 9

Common Side Effects and Management

Most frequent adverse events (occurring in >10% of patients): 6, 9

• Decreased appetite (49%)
• Weight decrease (18%)
• Insomnia (13%)
• Initial insomnia (9%)
• Irritability (9%)

Critical timing: These side effects peak in the first 4-12 weeks then typically diminish 6. Median time to onset: decreased appetite 13.5 days, insomnia 17 days, headache 22 days 6.

Management strategies:

• Appetite suppression: Give medication after breakfast; provide calorie-dense foods when medication wears off (evening); consider protein shakes
• Insomnia: Ensure morning dosing; avoid afternoon/evening doses; consider melatonin if persistent
• Irritability/mood lability: Often dose-related; may need dose reduction or switch to different stimulant

When to Consider Lisdexamfetamine vs. Methylphenidate

Lisdexamfetamine should be the preferred next option if methylphenidate fails after adequate trial. 5 Current guidelines recommend stimulants as first-line, with methylphenidate often tried first in many countries, but lisdexamfetamine is FDA-approved as first-line in the US 5.

Lisdexamfetamine advantages for a 12-year-old:

• Once-daily dosing (no school administration needed)
• 13-hour duration covers school plus homework/evening activities 7, 8
• Lower abuse potential due to prodrug design 10—important consideration entering adolescence
• Smoother effect profile (less rebound) compared to immediate-release formulations

Contraindications and Precautions

Absolute contraindications: 2, 1

• Hypersensitivity to amphetamine products
• Current or recent (within 14 days) MOAI use
• Symptomatic cardiovascular disease
• Moderate to severe hypertension
• Hyperthyroidism
• Glaucoma
• Active psychotic disorder

Relative contraindications requiring careful consideration:

• History of substance abuse (though lisdexamfetamine has lower abuse potential 10, 11)
• Tic disorders (though recent evidence suggests stimulants may not worsen tics 2)
• Seizure disorder (ensure controlled on anticonvulsants first 2)

Treatment Response Assessment

Define success as: 2

• ≥30% reduction in ADHD-RS-IV total score (minimum threshold)
• ≥50% reduction (robust response)
• CGI-Improvement score of 1 or 2
• Functional improvement at home AND school

If inadequate response after reaching 70 mg/day: 5

• Switch to methylphenidate (if lisdexamfetamine was first-line)
• Consider non-stimulants (atomoxetine, guanfacine, clonidine) as second-line
• Re-evaluate diagnosis and comorbidities
• Ensure behavioral interventions are in place

Integration with Behavioral Treatment

Medication should be combined with behavioral interventions. 4 For a 12-year-old, this includes:

• Parent training in behavior management
• School accommodations (504 plan or IEP)
• Organizational skills training
• Homework support strategies

The evidence shows medication alone produces larger effect sizes than behavioral therapy alone for core ADHD symptoms, but combination treatment optimizes overall functioning 3, 12, 4.

Key Pitfalls to Avoid

1. Underdosing: Don't stop at 30 mg if symptoms persist—titrate to effect up to 70 mg 1
2. Inadequate monitoring: Growth parameters must be tracked—stimulants affect height/weight trajectories 3, 6
3. Ignoring teacher input: School performance is critical outcome—always obtain teacher ratings 2
4. Premature discontinuation: Initial side effects (appetite, sleep) often improve after 4-12 weeks 6
5. Missing comorbidities: Screen for anxiety, depression, learning disabilities that may require additional intervention 4